Accessibility StatementSkip Navigation Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th... RICHMOND, Va., Nov. 20, 2025 /PRNewswire/ --Â Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with t ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI)Â today announced the launch of WSO Compliance Insights, a comprehensive compliance management solution designed to enhance credit risk management for private credit and CLO managers. This application, available through S&P Global Market Intelligence, utilizes real-time data streaming, enabling users to streamline compliance processes, eliminate end- of-day batch processing and improve decision-making capab ...

Core Insights - Olema Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 11,500,000 shares of common stock at a price of $19.00 per share, generating gross proceeds of approximately $218.5 million before expenses [1]. Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers. The company is advancing a pipeline that includes its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor in Phase 1 clinical study [5].

-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and remains on trial for more than 6 months -- -- Initial Disease Control Rate in efficacy evaluable patients of 71.4% with BRAF-mutated tumors: 5 of 7 patients achieved stable disease -- -- Favorable Safety Profile: PAS-0 ...

Accessibility StatementSkip Navigation IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- American Healthcare REIT, Inc. (NYSE: AHR; the "Company") announced today that it has commenced an underwritten public offering of 8,100,000Â shares of its common stock on a forward basis in connection with the forward sale agreement described below. RBC Capital Markets is acting as the underwriter for the offering. In connection with the offering, the Company expects to enter into a forward sale agreement with RBC Capital ...

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s pre ...

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition’s fireside discussion are as follows: E ...

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today announced that it expects to advance IKT-001 to a global pivotal Phase 3 cli ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - The article emphasizes an active investing strategy focused on identifying breakout stocks within specific price ranges, recommending to sell if prices drop below the lower boundary and to hold for gains if they surpass the upper boundary [1] Breakout Stock Identification - To identify breakout stocks, it is essential to calculate support and resistance levels, where support is the lower bound and resistance is the upper bound for stock movements [2] - Demand for a stock is lowest at its support level, while traders are more inclined to buy at the resistance level, making it crucial to focus on stocks nearing a breakout or those that have just surpassed resistance [3] Validating Breakouts - A genuine breakout occurs when the previous resistance level becomes the new support level, which can be confirmed through long-term price trend analysis [5] - The strength of support and resistance levels is determined through such studies, and correctly identifying breakout stocks can lead to significant returns [5] Screening Criteria - The screening criteria for breakout stocks include: - A percentage price change over four weeks between 10% and 20% [6] - Current price to 52-week high ratio greater than or equal to 0.9 [6] - Zacks Rank of less than or equal to 2 [6] - Beta for 60 months less than or equal to 2 [7] - Current price less than or equal to $20 [7] - These criteria narrow down the stock universe from over 6,853 to only 12 potential candidates [7] Featured Breakout Stocks - Orla Mining Ltd. (ORLA) focuses on acquiring, exploring, and developing mineral properties, with an expected earnings growth rate of 212% for the current year and a Zacks Rank of 2 [9] - FIGS, Inc. (FIGS) operates as a direct-to-consumer healthcare apparel company, with an expected earnings growth rate of 400% for the current year and a Zacks Rank of 1 [10] - Compass Therapeutics, Inc. (CMPX) is a clinical-stage oncology biopharmaceutical company with an expected earnings growth rate of 16.7% for the next quarter and a Zacks Rank of 2 [11]